An Extended Phase II Trial of Iodine-125 Methylene Blue for Sentinel Lymph Node Identification in Women with Breast Cancer
Authors:
- Anne E. DieboldADAnne E. Diebold
- Thomas MaloneyTMThomas Maloney
- Gregory EspenanGEGregory Espenan
- Yi-Zarn WangYWYi-Zarn Wang
- Shawn J. StaffordSSShawn J. Stafford
- Arthur CampACArthur Camp
- Daniel FreyDFDaniel Frey
- Charles ChappuisCCCharles Chappuis
- Eugene A. WolteringEWEugene A. Woltering
- 1 April 2013
- journal article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 216 (4) , 599-605
Abstract
The aim of this study was to determine if an intraoperative injection of iodine-125-labeled methylene blue ((125)I-MB) is a sensitive and effective method for detecting SLNs in women with breast cancer. Sixty-two women were enrolled in an extended phase II trial using (125)I-MB to guide SLNB. All patients were anesthetized and then injected subcutaneously with 1 mCi (125)I-MB in the outer quadrant of the areola. Radioactivity was detected in the axilla within 3 to 5 minutes. Fifty-eight of 62 (94%) patients had SLNs detected during their procedure. Mean (±SD) number of SLNs per patient was 1.8 ± 1.3 (range 0 to 6). A total of 112 nodes were dissected from 58 women; 110 of these nodes were considered sentinel. One hundred and eight (98%) nodes were hot, 98 (89%) nodes were blue, and 96 (87%) nodes were both hot and blue. Two women had complications; 1 had superficial skin staining and 1 had a superficial skin slough. Both healed uneventfully. No allergic reactions were observed. No radioactive uptake in the thyroid was seen. Iodine-125-labeled methylene blue can be mixed and administered in the operating room, improving hospital efficiency. Patient satisfaction is higher with (125)I-MB than with the technetium 99m sulfur colloid procedure because (125)I-MB does not produce localized burning and other adverse reactions associated with the traditional method, and 125I-MB is administered with the patient under anesthesia. Iodine-125 emits a lower-energy gamma ray than technetium 99m, lowering the surgeon's radiation exposure. Iodine-125-labeled methylene blue SLN identification is safe, cost effective, and produces equivalent outcomes compared with the traditional technique, making it an attractive alternative.Keywords
This publication has 15 references indexed in Scilit:
- A Phase I/II Trial of 125I Methylene Blue for One-Stage Sentinel Lymph Node BiopsyAnnals of Surgery, 2007
- Development of 125I‐methylene blue for sentinel lymph node biopsyJournal of Surgical Oncology, 2006
- A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancerThe American Journal of Surgery, 2005
- Utility of Breast Sentinel Lymph Node Biopsy Using Day-Before-Surgery Injection of High-Dose 99mTc-Labeled Sulfur ColloidAnnals of Surgical Oncology, 2001
- Highest Isotope Count Does Not Predict Sentinel Node Positivity in All Breast Cancer PatientsAnnals of Surgical Oncology, 2001
- Variability of the depth of supraclavicular and axillary lymph nodes in patients with breast cancer: is a posterior axillary boost field necessary?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- The AAPM/RSNA Physics Tutorial for ResidentsRadioGraphics, 1999
- The Sentinel Node in Breast Cancer — A Multicenter Validation StudyNew England Journal of Medicine, 1998
- Sentinel Lymph Node Biopsy in Breast Cancer: Initial Experience at Memorial Sloan-Kettering Cancer CenterJournal of the American College of Surgeons, 1998
- Development of Sentinel Node Targeting Technique in Breast Cancer PatientsThe Breast Journal, 1998